Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of the acid-suppression medicine. The net loss narrowed to $13.9 million from $30.0 million, despite operating expenses increasing to $66.4 million from $58.6 million. Phathom generated positive operating cash flow for a second consecutive quarter and ended the pe
0